# Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication

> **NCT02233049** · PHASE2 · UNKNOWN · sponsor: **Gustave Roussy, Cancer Campus, Grand Paris** · enrollment: 250 (estimated)

## Conditions studied

- Diffuse Intrinsic Pontine Glioma

## Interventions

- **DRUG:** Erlotinib
- **DRUG:** Everolimus
- **DRUG:** Dasatinib

## Key facts

- **NCT ID:** NCT02233049
- **Lead sponsor:** Gustave Roussy, Cancer Campus, Grand Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-10
- **Primary completion:** 2018-10
- **Final completion:** 2018-10
- **Target enrollment:** 250 (ESTIMATED)
- **Last updated:** 2018-07-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02233049

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02233049, "Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02233049. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*